摘要
肝细胞癌(HCC)是起源于肝细胞的恶性肿瘤,中国HCC患者80%发生于乙型肝炎病毒感染。HCC通常是一种富血供肿瘤,经动脉化疗栓塞(TACE)治疗一方面阻断肿瘤血供,同时在肿瘤局部聚集高浓度的化疗药物,对肿瘤细胞发挥最大限度的杀伤作用,被公认为HCC非手术治疗最常用方法之一。为此,中国医师协会介入医师分会专家们经讨论提出了《中国肝细胞癌经动脉化疗栓塞治疗(TACE)临床实践指南》,内容包括概述、适应证与禁忌证、围手术期处理、设备器械与药物准备、伦理与知情同意、患者术前准备、围手术期治疗、手术操作、并发症与处理、疗效评价与随访、综合治疗。
Hepatocellular carcinoma(HCC)is a malignant tumor originating from liver cells.Hepatitis B virus(HBV)infection is the main cause of HCC in 80%of Chinese patients.Pathologically,HCC is usually a kind of tumor with rich blood supply.Transarterial chemoembolization(TACE)can block the blood supply of the tumor,besides,high concentration of chemotherapeutic drugs can be accumulated within the tumor,and therefore TACE can kill tumor cells to the maximum extent.TACE has been recognized as one of the most commonly used non-surgical treatments for HCC.In view of this,after in-depth discussion the expertsfrom Chinese College of Interventionalists,Chinese Medical Doctor Association,put forward,《Chinese clinical practice guidelines for transarterial chemoembolization of hepatocellular carcinoma》.This《Guidelines》contains the following contents about TACE:brief introduction of HCC,indications and contraindications,perioperative treatment,euipment and drug preparation,ethical and informed consent,preparation of the patients,procedure,complications and management,evaluation and follow-up,and comprehensive therapy.
作者
中国医师协会介入医师分会
滕皋军
Chinese College of Interventionalists, Chinese Medical Doctor Association;Teng Gaojun(Zhongda Hospital,Southeast University,Nanjing 210009,China)
出处
《中华肝脏病杂志》
CAS
CSCD
北大核心
2019年第3期172-181,共10页
Chinese Journal of Hepatology
关键词
肝细胞癌
经导管动脉化疗栓塞术
临床实践
指南
Hepatocellular carcinoma
Transarterial chemoembolization
Clinical practice
Guideline
